Objective: The aim was to determine the contribution of Micro-biopsy to the diagnosis of patients with breast cancer. Material and methods: This was a 2-year retrospective observational study from January 1, 2019, to December 31, 2020. It concerned patients with breast pathologies who underwent Micro-biopsy. Results: We enrolled 360 patients with breast pathologies, 47 of whom underwent Micro-biopsy. The mean age of the patients was 43.0 years, with a predominance of females in 45 (95.7%) cases. The primary tumor was classified as T4 in 24 (51.2%) cases. Micro-biopsy yielded an average of 4 cores (4 and 10). Immunohistochemistry was performed abroad (cerba laboratory) in 40 (85.1%) patients. Hormone receptors were positive in 09 patients, including 6 (2.6%) with positive estrogen receptors and 3 (1.3%) with positive progesterone receptors. Her2-positive breast cancers accounted for 3 (1.3%) cases. The Ki67 proliferation index was ≥ 15% in 24 (40.4%) cases. According to the nature of the fine-needle biopsy specimen result, we notified 39 (83.0%) cases of cancer and 7 (15.0%) cases of benign tumor. Conclusion: This preliminary study enabled us to assess the contribution and reliability of Micro-biopsy in the diagnostic arsenal of breast cancer. Micro-biopsy should be performed for all breast nodules. Screening and awareness campaigns will make a considerable contribution to reducing the delay in diagnosis and the morbidity and mortality associated with breast cancer.
| Published in | International Journal of Clinical Oncology and Cancer Research (Volume 8, Issue 3) |
| DOI | 10.11648/j.ijcocr.20230803.15 |
| Page(s) | 72-76 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2023. Published by Science Publishing Group |
Micro-Biopsy, Breast Cancer, Guinea
| [1] | Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-49. https://doi.org/10.3322/caac.21660. |
| [2] | Zongo N, Windsouri M, Bambara HA, Some OR, Bambara AT, Ouangré E, et al. So-called "historical" necrotic breast cancers: a terrifying actuality in Africa. The case of Burkina Faso. Tropical Medicine and Health 2018; 28: 434-8. https://doi.org/10.1684/mst.2018.0854. |
| [3] | Jedy-Agba E, McCormack V, Adebamowo C, dos-Santos-Silva I. The stage at diagnosis of breast cancer in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health 2016; 4: e923-35. https://doi.org/10.1016/S2214-109X(16)30259-5. |
| [4] | International Agency for Research on Cancer. Guinea, Source: Globocan 2018. https://gco.iarc.fr/today/data/factsheets/populations/324-guinea-fact-sheets.pdf (accessed September 6, 2020). |
| [5] | International Agency for Research on Cancer. Guinea, Source: Globocan 2020. https://gco.iarc.fr/today/data/factsheets/populations/324-guinea-fact-sheets.pdf (accessed July 6, 2021). |
| [6] | White RR, Halperin TJ, Olson JA, Soo MS, Bentley RC, Seigler HF. Impact of Core-Needle Breast Biopsy on the Surgical Management of Mammographic Abnormalities. Ann Surg 2001; 233: 769-77. |
| [7] | James TA, Mace JL, Virnig BA, Geller BM. Preoperative needle biopsy improves the quality of breast cancer surgery. J Am Coll Surg 2012; 215: 562-8. https://doi.org/10.1016/j.jamcollsurg.2012.05.022. |
| [8] | Łukasiewicz E, Ziemiecka A, Jakubowski W, Vojinovic J, Bogucevska M, Dobruch-Sobczak K. Fine-needle versus core-needle biopsy - which one to choose in preoperative assessment of focal lesions in the breasts? Literature review. J Ultrason 2017; 17: 267-74. https://doi.org/10.15557/JoU.2017.0039. |
| [9] | Wang M, He X, Chang Y, Sun G, Thabane L. A sensitivity and specificity comparison of fine needle aspiration cytology and core needle biopsy in the evaluation of suspicious breast lesions: A systematic review and meta-analysis. The Breast 2017; 31: 157-66. https://doi.org/10.1016/j.breast.2016.11.009. |
| [10] | Nassar A. Core needle biopsy versus fine needle aspiration biopsy in breast-A historical perspective and opportunities in the modern era. Diagnostic Cytopathology 2011; 39: 380-8. https://doi.org/10.1002/dc.21433. |
| [11] | Vimpeli S-M, Saarenmaa I, Huhtala H, Soimakallio S. Wide-needle biopsy versus fine-needle aspiration biopsy in solid breast lesions: comparison of costs and diagnostic value. Acta Radiol 2008; 49: 863-9. https://doi.org/10.1080/02841850802235751. |
| [12] | Ciatto S, Houssami N, Ambrogetti D, Bianchi S, Bonardi R, Brancato B, et al. Accuracy and underestimation of malignancy of breast core needle biopsy: the Florence experience of over 4000 consecutive biopsies. Breast Cancer Res Treat 2007; 101: 291-7. https://doi.org/10.1007/s10549-006-9289-6. |
| [13] | Pagni P, Spunticchia F, Barberi S, Caprio G, Paglicci C. Use of Core Needle Biopsy rather than Fine-Needle Aspiration Cytology in the Diagnostic Approach of Breast Cancer. Case Rep Oncol 2014; 7: 452-8. https://doi.org/10.1159/000365141. |
| [14] | Günes ME. Comparison of the ultrasound-guided tru-cut biopsy with postoperative histopathology results in patients with breast mass. Ann Ital Chir 2018; 89: 30-5. |
| [15] | Samantaray S, Panda N, Besra K, Pattanayak L, Samantara S, Dash S. Utility of Tru-Cut Biopsy of Breast Lesions - An Experience in a Regional Cancer Center of a Developing Country. J Clin Diagn Res 2017; 11: EC36-9. https://doi.org/10.7860/JCDR/2017/23572.9548. |
| [16] | PISTOLESE CA, PERRETTA T, CLARONI G, ANEMONA L, SERVADEI F, COLLURA A, et al. A Prospective Evaluation of Tru-Cut Biopsy and Fine-needle Aspiration Cytology in Male Breast Cancer Detection. In Vivo 2020; 34: 3431-9. https://doi.org/10.21873/invivo.12182. |
| [17] | A. SC, R. RS, R. RH, N. SP, Prasad K. Fine needle aspiration cytology versus trucut biopsy in the diagnosis of breast cancer: a comparative study. Int Surg J 2017; 4: 3718. https://doi.org/10.18203/2349-2902.isj20174893. |
| [18] | Rikabi A, Hussain S. Diagnostic Usefulness of Tru-Cut Biopsy in the Diagnosis of Breast Lesions. Oman Med J 2013; 28: 125-7. https://doi.org/10.5001/omj.2013.32. |
| [19] | Krebs TL, Berg WA, Severson MJ, Magder LS, Goldberg PA, Campassi C, et al. Large-core biopsy guns: comparison for yield of breast tissue. Radiology 1996; 200: 365–8. https://doi.org/10.1148/radiology.200.2.8685327. |
| [20] | Oluwasola AG, Adeoye AO, Afolabi AO, Adeniji-Sofoluwe ATS, Salami A, Ajani MA, et al. Diagnostic accuracy of true-cut biopsy of breast lumps at University College Hospital, Ibadan. Afr J Med Med Sci 2015; 44: 157-62. |
| [21] | Aissa A, Ben Lassoued M, Alouini R. Breast microbiopsy: reliability according to BIRADS. Imagerie de la Femme 2014; 24: 1-13. https://doi.org/10.1016/j.femme.2014.02.001. |
APA Style
Bah Malick, Touré Alhassane Isamael, Keita Mamady, Conde Ibrahima Kalil, Souare Mamadou Bobo, et al. (2023). Results of Micro Biopsy (Tru-Cut) of Breast Cancer in Guinea. International Journal of Clinical Oncology and Cancer Research, 8(3), 72-76. https://doi.org/10.11648/j.ijcocr.20230803.15
ACS Style
Bah Malick; Touré Alhassane Isamael; Keita Mamady; Conde Ibrahima Kalil; Souare Mamadou Bobo, et al. Results of Micro Biopsy (Tru-Cut) of Breast Cancer in Guinea. Int. J. Clin. Oncol. Cancer Res. 2023, 8(3), 72-76. doi: 10.11648/j.ijcocr.20230803.15
AMA Style
Bah Malick, Touré Alhassane Isamael, Keita Mamady, Conde Ibrahima Kalil, Souare Mamadou Bobo, et al. Results of Micro Biopsy (Tru-Cut) of Breast Cancer in Guinea. Int J Clin Oncol Cancer Res. 2023;8(3):72-76. doi: 10.11648/j.ijcocr.20230803.15
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijcocr.20230803.15,
author = {Bah Malick and Touré Alhassane Isamael and Keita Mamady and Conde Ibrahima Kalil and Souare Mamadou Bobo and Sy Savané Mariame and Cisse Kalil and Cissé Mohamed Falilou and Traore Bangaly},
title = {Results of Micro Biopsy (Tru-Cut) of Breast Cancer in Guinea},
journal = {International Journal of Clinical Oncology and Cancer Research},
volume = {8},
number = {3},
pages = {72-76},
doi = {10.11648/j.ijcocr.20230803.15},
url = {https://doi.org/10.11648/j.ijcocr.20230803.15},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20230803.15},
abstract = {Objective: The aim was to determine the contribution of Micro-biopsy to the diagnosis of patients with breast cancer. Material and methods: This was a 2-year retrospective observational study from January 1, 2019, to December 31, 2020. It concerned patients with breast pathologies who underwent Micro-biopsy. Results: We enrolled 360 patients with breast pathologies, 47 of whom underwent Micro-biopsy. The mean age of the patients was 43.0 years, with a predominance of females in 45 (95.7%) cases. The primary tumor was classified as T4 in 24 (51.2%) cases. Micro-biopsy yielded an average of 4 cores (4 and 10). Immunohistochemistry was performed abroad (cerba laboratory) in 40 (85.1%) patients. Hormone receptors were positive in 09 patients, including 6 (2.6%) with positive estrogen receptors and 3 (1.3%) with positive progesterone receptors. Her2-positive breast cancers accounted for 3 (1.3%) cases. The Ki67 proliferation index was ≥ 15% in 24 (40.4%) cases. According to the nature of the fine-needle biopsy specimen result, we notified 39 (83.0%) cases of cancer and 7 (15.0%) cases of benign tumor. Conclusion: This preliminary study enabled us to assess the contribution and reliability of Micro-biopsy in the diagnostic arsenal of breast cancer. Micro-biopsy should be performed for all breast nodules. Screening and awareness campaigns will make a considerable contribution to reducing the delay in diagnosis and the morbidity and mortality associated with breast cancer.},
year = {2023}
}
TY - JOUR T1 - Results of Micro Biopsy (Tru-Cut) of Breast Cancer in Guinea AU - Bah Malick AU - Touré Alhassane Isamael AU - Keita Mamady AU - Conde Ibrahima Kalil AU - Souare Mamadou Bobo AU - Sy Savané Mariame AU - Cisse Kalil AU - Cissé Mohamed Falilou AU - Traore Bangaly Y1 - 2023/09/18 PY - 2023 N1 - https://doi.org/10.11648/j.ijcocr.20230803.15 DO - 10.11648/j.ijcocr.20230803.15 T2 - International Journal of Clinical Oncology and Cancer Research JF - International Journal of Clinical Oncology and Cancer Research JO - International Journal of Clinical Oncology and Cancer Research SP - 72 EP - 76 PB - Science Publishing Group SN - 2578-9511 UR - https://doi.org/10.11648/j.ijcocr.20230803.15 AB - Objective: The aim was to determine the contribution of Micro-biopsy to the diagnosis of patients with breast cancer. Material and methods: This was a 2-year retrospective observational study from January 1, 2019, to December 31, 2020. It concerned patients with breast pathologies who underwent Micro-biopsy. Results: We enrolled 360 patients with breast pathologies, 47 of whom underwent Micro-biopsy. The mean age of the patients was 43.0 years, with a predominance of females in 45 (95.7%) cases. The primary tumor was classified as T4 in 24 (51.2%) cases. Micro-biopsy yielded an average of 4 cores (4 and 10). Immunohistochemistry was performed abroad (cerba laboratory) in 40 (85.1%) patients. Hormone receptors were positive in 09 patients, including 6 (2.6%) with positive estrogen receptors and 3 (1.3%) with positive progesterone receptors. Her2-positive breast cancers accounted for 3 (1.3%) cases. The Ki67 proliferation index was ≥ 15% in 24 (40.4%) cases. According to the nature of the fine-needle biopsy specimen result, we notified 39 (83.0%) cases of cancer and 7 (15.0%) cases of benign tumor. Conclusion: This preliminary study enabled us to assess the contribution and reliability of Micro-biopsy in the diagnostic arsenal of breast cancer. Micro-biopsy should be performed for all breast nodules. Screening and awareness campaigns will make a considerable contribution to reducing the delay in diagnosis and the morbidity and mortality associated with breast cancer. VL - 8 IS - 3 ER -
Information
Email: